Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for Chikungunya
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Chikungunya or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on Chikungunya and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Chikungunya fever in Africa: a systematic review. Since the identification of chikungunya virus (CHIKV), sporadic cases and outbreaks were reported in several African countries, on the Indian subcontinent, and in south-east Asia. In the last 20 years, there is a growing number of reports of CHIKV infections from African countries, but the overall picture of its circulation at the continent level remains ill-characterized because of under-diagnosis and under-reporting. Moreover, the public
Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial. Chikungunya virus (CHIKV) is a mosquito-borne Alphavirus prevalent worldwide. There are currently no licensed vaccines or therapies.To evaluate the safety and tolerability of an investigational CHIKV virus-like particle (VLP) vaccine in endemic regions.This was a randomized, placebo-controlled, double-blind, phase 2 clinical trial to assess the vaccine VRC-CHKVLP059-00-VP (CHIKV (...) is the dilution of sera that inhibits 50% infection in viral neutralization assay-geometric mean titers (GMTs) of neutralizing antibodies of the vaccine group (46; 95% CI, 34-63) and the placebo group (43; 95% CI, 32-57). Eight weeks following the first administration, the EC50 GMT in the vaccine group was 2005 (95% CI, 1680-2392) vs 43 (95% CI, 32-58; P < .001) in the placebo group. Durability of the immune response was demonstrated through 72 weeks after vaccination.Among healthy adults in a chikungunya
Chikungunya Virus Infection Outcome: A Systematic Review of Host Genetics. Background: Chikungunya virus (CHIKV) is a global concern, inducing chikungunya fever and trigging an arthritogenic chronic phase beyond some severe forms. Outcomes of CHIKV infections in humans are dependent on genetic variations. Here, a systematic review was performed to show evidence of genetic variations on infection outcomes of patients.Methods: Searches were performed in Scopus, SciELO, MEDLINE/PubMed, Web
Prevalence of and risk factors for long-term disabilities following chikungunya virus disease: A meta-analysis. The main aim of this study was to investigate the percentage of individuals who developed long-term disabilities after chikungunya virus (CHIKV) disease on the basis of follow up time interval and its associated risk factors.In this meta-analysis, electronic databases PubMed, Science Direct and Google Scholar were searched to identify cohort studies of CHIKV disease from January 2000
Reply to Simon et al. on "The neurological complications of chikungunya virus: A systematic review". 30357983 2019 10 28 2020 03 09 1099-1654 28 6 2018 11 Reviews in medical virology Rev. Med. Virol. Reply to Simon et al. on "The neurological complications of chikungunya virus: A systematic review". e2012 10.1002/rmv.2012 Mehta Ravi R 0000-0001-8211-1721 National Institute for Health Research Health Protection Research Unit in Emerging and Zoonotic Infections, University of Liverpool, Liverpool (...) Research Council United Kingdom G116/194 MRC_ Medical Research Council United Kingdom RP-PG-0108-10048 DH_ Department of Health United Kingdom EME/12/205/28 DH_ Department of Health United Kingdom Letter Comment 2018 10 24 England Rev Med Virol 9112448 1052-9276 IM Rev Med Virol. 2018 May;28(3):e1978 29671914 Chikungunya Fever Chikungunya virus Humans Nervous System Diseases 2018 09 12 2018 09 13 2018 10 26 6 0 2019 10 29 6 0 2018 10 26 6 0 ppublish 30357983 10.1002/rmv.2012
Chikungunya virus in Asia - Pacific: a systematic review. Chikungunya virus (CHIKV) is a mosquito-borne pathogen that causes an acute febrile syndrome and severe, debilitating rheumatic disorders in humans that may persist for months. CHIKV's presence in Asia dates from at least 1954, but its epidemiological profile in the region remains poorly understood. We systematically reviewed CHIKV emergence, epidemiology, clinical features, atypical manifestations and distribution of virus genotypes (...) genotype now predominant. Our findings indicate a substantial but poorly documented burden of CHIKV infection in the Asia-Pacific region. An evidence-based consensus on typical clinical features of chikungunya could aid in enhanced diagnosis and improved surveillance of the disease.
[Meta-analysis of the usefulness of ELISA, PCR, and immunochromatography for the diagnosis of ChikungunyaMeta-anÃ¡lise da utilidade dos exames ELISA, PCR e imunocromatografia no diagnÃ³stico de febre chikungunya]. Evaluate the usefulness of ELISA, PCR, and immunochromatography for the diagnosis of Chikungunya.A meta-analysis of studies reporting diagnostic validity data was performed, using an ex-ante protocol with six search strategies in three multidisciplinary databases. Replicability (...) %) between 2009 and 2015, using a combination of clinical symptoms, RT-PCR, ELISA, neutralization assay, or viral isolation as the reference test. The population consisted of 1 108 healthy individuals, 394 with another infection (mainly dengue), and 1 288 with Chikungunya. In IgM ELISA and qPCR, the sensitivity and specificity were greater than 90%, the positive probability quotient was greater than 10, the negative probability quotient was less than 0.1, the diagnostic odds ratio was greater than 100
Incidence of articular pain and arthritis after chikungunya fever in the Americas: A systematic review of the literature and meta-analysis. To estimate the incidence of chronic articular symptoms after chikungunya virus infection of patients from the American continent.We performed a systematic review of the literature using the MEDLINE, Web of Science and Scopus databases. We included only cohort studies conducted in the American continent reporting the incidence of chronic articular symptoms (...) after chikungunya virus acute infection. The quality of the selected studies was evaluated through the Newcastle-Ottawa Scale for non-randomized studies and relevant data were extracted. The pooled incidence of post-chikungunya chronic symptoms was estimated using a random-effect model meta-analysis. Heterogeneity was assessed by Q of Cochrane and its P-value, Tau2 and I2. Subgroup analysis was performed, and studies were stratified by quality, sample size, region, country, period of follow-up
Chikungunya virus infection in Indonesia: a systematic review and evolutionary analysis. Despite the high number of chikungunya cases in Indonesia in recent years, comprehensive epidemiological data are lacking. The systematic review was undertaken to provide data on incidence, the seroprevalence of anti-Chikungunya virus (CHIKV) IgM and IgG antibodies, mortality, the genotypes of circulating CHIKV and travel-related cases of chikungunya in the country. In addition, a phylogenetic (...) and evolutionary analysis of Indonesian CHIKV was conducted.A systematic review was conducted to identify eligible studies from EMBASE, MEDLINE, PubMed and Web of Science as of October 16th 2017. Studies describing the incidence, seroprevalence of IgM and IgG, mortality, genotypes and travel-associated chikungunya were systematically reviewed. The maximum likelihood phylogenetic and evolutionary rate was estimated using Randomized Axelerated Maximum Likelihood (RAxML), and the Bayesian Markov chain Monte Carlo
A systematic review of individual and community mitigation measures for prevention and control of chikungunya virus. Chikungunya is a mosquito-borne virus transmitted by mosquitoes from the Aedes genus. The virus, endemic to parts of Asia and Africa, has recently undergone an emergence in other parts of the world where it was previously not found including Indian Ocean Islands, Europe, the Western Pacific and the Americas. There is no vaccine against chikungunya virus, which means (...) that prevention and mitigation rely on personal protective measures and community level interventions including vector control.A systematic review (SR) was conducted to summarize the literature on individual and community mitigation and control measures and their effectiveness. From a scoping review of the global literature on chikungunya, there were 91 articles that investigated mitigation or control strategies identified at the individual or community level. Of these, 81 were confirmed as relevant
Chikungunya virus infection Chikungunya virus infection - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search Chikungunya virus infection Last reviewed: February 2019 Last updated: November 2018 Summary Notifiable condition. It is important to distinguish from dengue fever and Zika virus infection, which are transmitted by the same vector. Most patients fully recover, but some develop chronic joint disease characterised (...) of antibodies. Real-time reverse transcription polymerase chain reaction can be used to determine whether a patient is infected with chikungunya, Zika, or dengue virus in one test. Co-infection may occur. There is no specific vaccine or treatment. Avoidance of mosquito bites is the best method of prevention. Definition Chikungunya virus (also known as CHIKV) is an alphavirus transmitted by the Aedes species of mosquitoes. Chikungunya means 'that which bends up' in the Makonde language (spoken in a border
Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial. Chikungunya fever is an emerging viral disease and substantial threat to public health. We aimed to assess the safety, tolerability, and immunogenicity of a live-attenuated, measles-vectored chikungunya vaccine (MV-CHIK).In this double-blind, randomised, placebo-controlled and active-controlled phase 2 trial, we (...) , which was maintained by use of sterile saline as a placebo injection. The primary endpoint was immunogenicity, defined as the presence of neutralising antibodies against chikungunya virus, at day 56, which is 28 days after one or two immunisations. The primary endpoint was assessed in all participants who completed the study without major protocol deviations (per-protocol population) and in all randomised participants who received at least one study treatment (modified intention-to-treat population
2018LancetControlled trial quality: predicted high
Treatment of Chronic Chikungunya Arthritis With Methotrexate: A Systematic Review Chikungunya virus infection is a rapidly emerging global viral infection that can cause chronic, debilitating arthritis that in some ways mimics rheumatoid arthritis. The aim of this study was to evaluate the available evidence regarding the efficacy and safety of methotrexate (MTX), a therapy that is widely used in rheumatoid arthritis, for the treatment of chronic chikungunya arthritis.A systematic literature (...) search was performed to identify all published trials that evaluated MTX as monotherapy or combination therapy in patients with chronic chikungunya arthritis. PubMed, SciELO, Scopus, and Cochrane Library databases were searched from study inception to August 2017. We also searched Google Scholar, the International Clinical Trials Registry Platform Search Portal, and clinicaltrials.gov.Among 131 possibly relevant studies, 6 met our criteria for evaluation: 4 were retrospective studies, 1 was a non
Chikungunya chronic disease: a systematic review and meta-analysis. Chikungunya is a mosquito-borne disease caused by an arthritogenic alphavirus, with four genotypes: East Central South African (ECSA), West African, ECSA-diverged or Indian Ocean Lineage (IOL) and Asian lineage. Overall, the disease is self-limited; however, in some patients, joint pain and other non-specific symptoms can last for months or years. This systematic review and meta-analysis aims to estimate the proportion (...) of people that self-report chikungunya-related chronic non-specific symptoms.Medline, EMBASE, Global Health Library and Scopus were searched for articles published before March 2017. Case-control, cohort, cross-sectional, clinical trials studies and outcome-independent case series were eligible. It was estimated that the proportion of patients who did not recover, by virus genotype, and by the time between disease onset and assessment of chronic symptoms.A total of 38 studies were included in the review
Mother-to-child transmission of Chikungunya virus: A systematic review and meta-analysis Chikungunya virus (CHIKV) is an emerging arboviral infection with a global distribution and may cause fetal and neonatal infections after maternal CHIKV-infections during gestation.We performed a systematic review to evaluate the risk for: a) mother-to-child transmission (MTCT), b) antepartum fetal deaths (APFD), c) symptomatic neonatal disease, and d) neonatal deaths from maternal CHIKV-infections during
Global prevalence and distribution of coinfection of malaria, dengue and chikungunya: a systematic review. Malaria, Dengue and Chikungunya are vector borne diseases with shared endemic profiles and symptoms. Coinfections with any of these diseases could have fatal outcomes if left undiagnosed. Understanding the prevalence and distribution of coinfections is necessary to improve diagnosis and designing therapeutic interventions.We have carried out a systematic search of the published literature (...) based on PRISMA guidelines to identify cases of Malaria, Dengue and Chikungunya coinfections. We systematically reviewed the literature to identify eligible studies and extracted data regarding cases of coinfection from cross sectional studies, case reports, retrospective studies, prospective observational studies and surveillance reports.Care full screening resulted in 104 publications that met the eligibility criteria and reported Malaria/Dengue, Dengue/Chikungunya, Malaria/Chikungunya and Malaria
Treatment of chikungunya chronic arthritis: A systematic review. Chikungunya (CHIK) is a tropical arbovirus, transmitted by the female mosquito Aedes aegypti and Aedes albopictus. In Brazil, there have been cases reported since 2014. The initial manifestations of this virus are sudden onset high fever, headache, chills, rashes, myalgia and intense joint pain. Usually, CHIK presents the acute and chronic phases, the latter characterized by bilateral polyarthralgia, which can last for months
Evidence of previous but not current transmission of chikungunya virus in southern and central Vietnam: Results from a systematic review and a seroprevalence study in four locations. Arbovirus infections are a serious concern in tropical countries due to their high levels of transmission and morbidity. With the outbreaks of chikungunya (CHIKV) in surrounding regions in recent years and the fact that the environment in Vietnam is suitable for the vectors of CHIKV, the possibility of transmission (...) in central and southern Vietnam, but no evidence of recent sustained transmission. When transmission of CHIKV did occur, it appeared to be widespread and affect a geographically diverse population. The estimated susceptibility of the population to chikungunya is continually increasing, therefore the possibility of future CHIKV transmission in Vietnam remains.